Increased sales and profits latest quarter and new market for insulin. - increases the value of the business to be sold.
No comments in the annual report as to the intentions of the Bioton Sa for the sale of SIE and directors comments are cautious. The facts are SIE have established products in a number of Asian markets and as they are first into markets that is a significant advantage. The sales of insulin in many countries has only started and to be registered and be selling is a real achievement.
There must be Asian investors and Chinese investors interested in the acquisition of SIE - the opportunity to acquire SIE as a going concern with a wide range of products registered and in Asian market is a unique opportunity.
SIE Price at posting:
2.4¢ Sentiment: Buy Disclosure: Held
